Literature DB >> 9559838

Smoking and obesity in relation to the etiology and disease progression of prostate cancer in Japan.

Y Furuya1, S Akimoto, K Akakura, H Ito.   

Abstract

BACKGROUND: Various risk factors have been investigated concerning the etiology of prostate carcinoma, but many questions about the significance of the risk factors remain unanswered. To evaluate the relationship between smoking and obesity in prostate cancer, a case-control study was performed.
METHODS: Between 1986 and 1995, 329 patients with untreated prostate cancer and 188 patients with benign prostate hyperplasia (control patients) were evaluated according to their smoking habits and the degree of obesity. Also, the progression of prostate cancer in relationship to smoking and obesity was examined.
RESULTS: Smoking and obesity were not risk factors for the development of prostate cancer (odds ratio, 0.986, 0.836; 95% confidence interval, 0.69-1.41, 0.57-1.24, respectively). Nor were smoking or obesity a risk factor for survival in stage D2 patients, however, in stage B1-D1 patients, obese men had a tendency for disease progression.
CONCLUSION: This study demonstrated that neither smoking nor obesity increase the risk of developing prostate cancer, or the risk of disease progression in prostate cancer patients. However, obese men have a tendency for progression of stage B1-D1 prostate cancer although further studies are necessary to confirm this finding.

Entities:  

Mesh:

Year:  1998        PMID: 9559838     DOI: 10.1111/j.1442-2042.1998.tb00261.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

1.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Examining the relationship between obesity and prostate cancer.

Authors:  Stephen J Freedland; William J Aronson
Journal:  Rev Urol       Date:  2004

3.  Obesity and prostate cancer detection: insights from three national surveys.

Authors:  Niyati Parekh; Yong Lin; Robert S Dipaola; Stephen Marcella; Grace Lu-Yao
Journal:  Am J Med       Date:  2010-09       Impact factor: 4.965

4.  Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.

Authors:  Neeraj K Saxena; Ping P Fu; Arumugam Nagalingam; Jason Wang; Jeffrey Handy; Cynthia Cohen; Mourad Tighiouart; Dipali Sharma; Frank A Anania
Journal:  Gastroenterology       Date:  2010-07-13       Impact factor: 22.682

5.  Associations between estrogen receptor genetic polymorphisms, smoking status, and prostate cancer risk: a case-control study in Japanese men.

Authors:  Xi Lu; Yuko Yamano; Hiroyuki Takahashi; Masahide Koda; Yuki Fujiwara; Aya Hisada; Wataru Miyazaki; Takahiko Katoh
Journal:  Environ Health Prev Med       Date:  2015-08-07       Impact factor: 3.674

6.  Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis.

Authors:  Luisa Zuccolo; Ross Harris; David Gunnell; Steven Oliver; Jane Athene Lane; Michael Davis; Jenny Donovan; David Neal; Freddie Hamdy; Rebecca Beynon; Jelena Savovic; Richard Michael Martin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

7.  Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells.

Authors:  Dayanand D Deo; Ashwin P Rao; Saideep S Bose; Allal Ouhtit; Surendra B Baliga; Shilpa A Rao; Bruce J Trock; Rajesh Thouta; Madhwa H G Raj; Prakash N Rao
Journal:  J Biomed Biotechnol       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.